Hematopoietic and Lymphoid Cell Neoplasm
NCI Definition: A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes. 
Hematopoietic and lymphoid cell neoplasms most frequently harbor alterations in TP53, TET2, DNMT3A, ASXL1, and JAK2 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, DNMT3A Mutation, and TET2 Mutation are the most common alterations in hematopoietic and lymphoid cell neoplasm .
There is 1 clinical trial for hematopoietic and lymphoid cell neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains hematopoietic and lymphoid cell neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
Atezolizumab is the most common intervention in hematopoietic and lymphoid cell neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.